Search This Blog

Wednesday, May 12, 2021

Merck KGaA 1Q Earnings, Sales Rise

 Merck KGaA said Wednesday that earnings and revenue rose in the first quarter, driven by all its business division but especially life science.

After-tax profit at the German pharmaceuticals-and-chemicals company came in at 748 million euros ($908.9 million) for the quarter, up from EUR458 million in the same quarter a year prior.

Earnings before interest, taxes, depreciation and amortization before one-time items, or Ebitda pre, stood at EUR1.51 billion, compared with EUR1.18 billion in the first quarter of 2020, as the company had communicated in a preliminary statement on May 4.

Net sales came in at EUR4.63 billion, up from EUR4.37 billion, which had also already been communicated in a preliminary statement.

For the full year, sales are expected to come in between EUR18.5 billion and EUR19.5 billion, a guidance increase that had been previously communicated in a preliminary statement. Ebitda pre is seen coming in between EUR5.4 billion and EUR5.8 billion, the company said. That compares with a previous guidance of strong organic growth.

https://www.marketscreener.com/quote/stock/MERCK-KGAA-436395/news/Merck-KGaA-1Q-Earnings-Sales-Rise-33231908/

Bayer 1Q Net Profit Rose, Backs 2021 Outlook

 Bayer AG on Wednesday reported a rise in net profit despite slightly lower sales and backed its outlook for the year.

The German pharmaceutical and chemical conglomerate posted net profit of 2.09 billion euros ($2.54 billion), up from EUR1.49 billion in the same quarter of 2020.

Earnings before interest, taxes, depreciation and amortization before special items were EUR4.12 billion, slightly down from EUR4.39 billion the year prior. Sales stood at EUR12.33 billion in the period, versus EUR12.85 billion the previous year, the company said.

Free cash flow plunged to negative EUR3.23 billion from negative EUR793 million the year prior, due to settlement payments for litigations in the U.S., Bayer said.

Regarding litigation involving its glyphosate-based Roundup pesticide, Bayer said that about 96,000 claims are covered by settlement agreements, and that it continues to negotiate with plaintiff counsels to reach agreement on remaining cases.

The company's agricultural business, known as Crop Science, saw a slight decline in sales for the quarter, to EUR6.65 billion from EUR6.83 billion the year prior, but said that sales of herbicides gained volume in all regions on higher prices for Roundup.

Sales of pharmaceuticals remained at the prior-year level, Bayer said, while consumer health products suffered a hit from lower sales of cough and cold products prompted by continuing hygiene measures and lockdowns.

The company backed its outlook for 2021. It had previously said it expected sales between around EUR42 billion and EUR43 billion for the year, with an Ebitda before special items of EUR11.2 billion to EUR11.5 billion, both on a currency-adjusted basis.

https://www.marketscreener.com/quote/stock/BAYER-AG-436063/news/Bayer-1Q-Net-Profit-Rose-Backs-2021-Outlook-Update-33232775/

Lab supplier Merck KGaA says U.S. Defense Production Act poses challenge

 Merck KGaA on Wednesday said that U.S. regulations that give priority to U.S. government contracts to purchase COVID-19 vaccines are a challenge as it seeks to meet soaring demand for its lab equipment and supplies across the globe.

"We are actively expanding our capacity to be able to supply this unprecedented and ever increasing demand. Is this being a challenge? Obviously it is being a challenge," Chief Executive Belen Garijo said in a media briefing when asked what impact the U.S. Defense Production Act is having on its ability to serve vaccine makers elsewhere in the world.

She said U.S. law required that a preference be given to so-called rated state orders for COVID-19 programs over any other orders.

"For us, all our customers and all the other COVID-19 programs are very crucial and we are making capacity expansion a top priority of our agenda," she said, pointing to investment projects both in the United States and Europe.

Under the U.S. priority access program, the government has laid claim not only to finished COVID-19 vaccines but also to vaccine components and equipment.

Germany's CureVac, which is gearing up to publish results of a COVID-19 vaccine trial, said last week that U.S. export restrictions on already tight supplies of materials were making it impossible to predict its short-term production ramp-up in Europe.

Merck in March unveiled plans to invest 25 million euros ($29.9 million) to make disposable plastic materials for bioreactors in France, an essential input for COVID-19 vaccine manufacturing.

The new site, Merck's first such facility in Europe, will likely come on stream at the end of this year, Garijo reiterated on Wednesday.

Merck in December announced a combined $47 million investment at U.S. production facilities in Massachusetts and New Hampshire, also to produce supplies for makers of COVID-19 vaccines and therapies.

Merck, which competes in lab equipment with Thermo Fisher and Sartorius, has another site for single-use plastic bags for bioreactors in Wuxi, China.

https://www.marketscreener.com/quote/stock/MERCK-KGAA-436395/news/Merck-nbsp-Lab-supplier-Merck-KGaA-says-U-S-Defense-Production-Act-poses-challenge-33234553/

Pfizer seeks UK approval for use of COVID-19 vaccine in teenagers

 Pfizer is seeking British approval for the use of its COVID-19 vaccine among 12- to 15-year olds and has submitted data to the health regulator, a company representative said on Tuesday, paving the way for inoculation of adolescents in the country.

The vaccine, developed along with Germany's BioNTech , has already been approved in the United States and Canada for use against COVID-19 infections in children and young adults.

"I can confirm we've submitted data on the efficacy of the vaccine in 12 to 15 year olds for review by U.K. MHRA," an official for the U.S. drugmaker told Reuters, referring to the Medicines and Healthcare products Regulatory Agency.

Health officials are banking on vaccines to end the pandemic, but are worried that some parents will be hesitant in vaccinating their children due to fears of potential side effects and long-term risks. Kids under 12 have so far been less susceptible to COVID-19.

The drugmakers have said their shot is safe, effective and produced robust antibody responses in children as young as 12 years of age.

The vaccine, which uses mRNA technology to deliver instructions to the human body to build immunity against the illness, is also being tested in children aged two to 11, with safety and efficacy data expected in September, Pfizer has said.

Although other drugmakers, including AstraZeneca, Moderna and Johnson & Johnson , are working on vaccines for children, Pfizer and BioNTech have managed to steal a march.

Pfizer's vaccine, branded Comirnaty, is also under an EU review for use in children aged 12 to 15 years, with the head of the region's medicines regulator saying an approval could come as early as end-May.

The Telegraph earlier reported on the British review, saying the vaccine was likely to be approved before the end of July.

https://finance.yahoo.com/news/1-pfizer-asks-uk-regulator-211227509.html

Samsung BioLogics to produce Pfizer's COVID-19 vaccine

 Samsung BioLogics Co Ltd is in talks with Pfizer Inc to begin production of the U.S. drugmaker's COVID-19 vaccine in South Korea as early as in August, a South Korean newspaper reported on Wednesday.

The biotech arm of Samsung Group has been revamping production lines at its plant in Songdo to produce the Pfizer vaccine, which was jointly developed by BioNTech, the Korea Economic Daily said.

The plant can make up to 1 billion doses per year, the report said, quoting an unnamed high-level government official.

Samsung BioLogics and Pfizer were not immediately available for comment. The Korea Disease Control and Prevention Agency (KDCA) in charge of COVID-19 vaccine procurement was also not immediately available for comment.

South Korea has a contract with Pfizer to purchase 66 million doses of its COVID-19 vaccine. It also has contracts to acquire a total of 192 million doses from other developers including Moderna Inc, AstraZeneca Plc, Johnson & Johnson's and Novavax. 

https://finance.yahoo.com/news/samsung-biologics-produce-pfizers-covid-232807272.html

Tuesday, May 11, 2021

Biotech firm Ginkgo to merge with Harry Sloan-led SPAC in $17.5 billion deal

 Ginkgo said on Tuesday it was planning to go public through a merger with a blank-check vehicle backed by former Hollywood executives Harry Sloan and Jeff Sagansky, in one of the biggest such deals that values the biotech company at $17.5 billion.

The merger is expected to fetch $2.5 billion in proceeds for the combined entity, the companies said, including $775 million from institutional investors such as Baillie Gifford, Putnam Investments and accounts advised by ARK Investment Management. Reuters reported on the company’s plans last month.

Founded by a team of scientists at Massachusetts Institute of Technology in 2009, Ginkgo makes genetic engineering tools for industries across agriculture, pharmaceuticals and cosmetics. It currently runs 70 programs with customers including Moderna and Cargill.

The deal gives Ginkgo a pre-money equity valuation of $15 billion. The company was valued at $4.86 billion during a private raise in May 2020, according to PitchBook data. It’s also backed by Bill Gates’ private investment firm Cascade Investment.

“Raising capital allows us to build bigger facilities and add support services that make it easier for people to develop on our platform. The public market is a good source of that,” Ginkgo co-founder and Chief Executive Officer Jason Kelly said.

Boston-based Ginkgo expects $150 million in revenue in 2021, a 96% jump from a year earlier. It received a $1.1 billion loan from the U.S. government in November for COVID-19 testing and production of raw materials for therapies that may help address future pandemics.

Special purpose acquisition vehicles, or SPACs, are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.

Soaring Eagle is also backed by SPAC veteran Eli Baker, who is its chief financial officer.

Sloan, a former CEO of Metro Goldwyn Mayer, and Sagansky took gaming firms DraftKings Inc and Skillz Inc public last year through similar deals.

The Ginkgo deal signals a rebound in activity after Wall Street appetite for new SPACs showed signs of waning during a period that saw regulators weigh measures to rein in the pace of dealmaking through blank-check companies.

Soaring Eagle raised $1.7 billion through an IPO in February.

https://www.reuters.com/article/gingkgo-ma-soaring-eagle/update-3-biotech-firm-ginkgo-to-merge-with-harry-sloan-led-spac-in-17-5-bln-deal-idUSL1N2MZ030

Missouri, Tennessee join U.S. states cutting pandemic payments

 The governors of Missouri and Tennessee are joining five other Republican-led states in ending all federally funded pandemic-related unemployment benefits this summer, saying the extra money is keeping those out of work from rejoining the labor force and making it hard for employers to fill jobs.

“While these benefits provided supplementary financial assistance during the height of COVID-19, they were intended to be temporary, and their continuation has instead worsened the workforce issues we are facing,” Missouri Gov. Mike Parson said in announcing the decision on Tuesday.

It’s a contention widely shared by businesses and was behind the U.S. Chamber of Commerce’s call Friday to end the aid nationally after a government report showed employers hired only 266,000 in April, about a quarter of what had been expected.

The benefits were extended as part of the $1.9 trillion government aid package backed by the Biden administration and passed by a narrowly divided Congress.

Alabama, Arkansas, Mississippi, Montana, and South Carolina have also announced plans to terminate the benefits they blame for slowing hiring.

But it’s an idea that is hotly disputed.

“Cutting pandemic UI benefits now, as some states have done or are considering, will not just hurt workers who are depending on federal benefits while they cannot find work or are unable to work, it will also drag on the economy, as those benefits are supporting spending,” wrote the left-leaning Economic Policy Institute’s Josh Bivens and Heidi Shierholz.

Federal Reserve policymakers, who typically try to stay out of partisan debates, on Tuesday pointed to factors other than unemployment benefits for keeping workers on the sidelines.

“People do actually want to go back to work; they are willing to do that,” Federal Reserve Governor Lael Brainard said on Tuesday, adding that school closures meant many needed to look after children and couldn’t look for jobs.

And they fear exposure to a virus that still claims nearly 700 American lives a day.

In April when the data for the jobs report was collected, only one in four working-age Americans were fully vaccinated, she said.

NO MORE $300

All seven states ending the pandemic benefits for workers have vaccination rates below the national average. All also have below-average seven-day averages for new cases.

Collectively, about 5.5% of the labor force in the seven states that have announced plans to end pandemic benefits were drawing on some form of unemployment insurance, government data shows.

That compares with 13.7% in California and 9.4% in Texas.

But those benefits - which include an extra $300 a week in pay for the unemployed - may loom larger for workers in states where wages are relatively lower, or regular unemployment benefits are smaller.

The extra sum more than doubles Tennessee’s maximum weekly benefit of $275, for example.

St. Louis Fed President James Bullard said such state-by-state differentials could mean that in some places, pandemic benefits could indeed be holding back some workers.

“Rural labor markets are very different from urban ones,” he said, and some cities are more expensive than others. The same $300 “incentivizes people very differently.”

The extra unemployment benefit “is a factor,” he said. “It is not the only factor.”

https://www.reuters.com/article/us-usa-economy-unemployment/missouri-tennessee-join-u-s-states-cutting-pandemic-payments-idUSKBN2CS312